哌拉西林-他唑巴坦治疗社区获得性肺炎疗效观察  

作　　者：杨炜[1] 陈力[2] 

机构地区：[1]四川省成都市第六人民医院呼吸内科,610051 [2]四川省成都铁路中心医院老年科,610081

出　　处：《浙江临床医学》2009年第6期579-581,共3页Zhejiang Clinical Medical Journal

摘　　要：目的 探讨哌拉西林-他唑巴坦治疗社区获得性肺炎的临床疗效。方法将200例患者随机分为观察组和对照组各100例，观察组应用哌拉西林-他唑巴坦4．5g治疗，静脉滴注，2次／d，用药8～12d；对照组使用头孢曲松钠2g，静脉滴注，1次／d，用药8～12d；比较两组临床疗效。结果治疗组有效率为95．0％，对照组有效率为73．0％，两组比较差异有统计学意义（P〈0．01）。结论哌拉西林-他唑巴坦对社区获得性肺炎有较好疗效，具有一定的临床价值，值得临床应用推广。Objective To explore the clinical therapeutic effect of piperacillin and tazobactam on community acquired pneumonia. Methods 200 patients with community acquired pneumonia were divided randomly into the intervention group（ 100 cases） and the control group（ 100 cases） ,the intervention group were treated with piperacillin and tazobactam 4.5g intravenously, twice a day for 8 -12days;the control group were treated with ceftriaxone 2g intravenously, once a day for 8 - 12 days, the clinical therapeutic effect was compared. Results Of the trial group, the effective rate was 95.0%, of the control group, the effective rate was 73.0%, and there is significant difference between them（P 〈 0. 01 ）. Conclusion Piperacillin and tazobactam have better therapeutic effect on community acquired pneumonia, and hence is worthy of being recommended in clinical practice.

关 键 词：哌拉西林-他唑巴坦 肺炎 社区获得性感染 

分 类 号：R563.1[医药卫生—呼吸系统] R978.11[医药卫生—内科学]